DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation

Phase 2

Completed

Conditions: Fungus Diseases

Interventions: Drug: AmBisome

First Posted Date: 2006-05-16

Last Posted Date: 2010-02-12

Lead Sponsor: Gilead Sciences

Target Recruit Count: 34

Registration Number: NCT00326157

Locations: 🇮🇹
Gilead Sciences, Milan, Italy

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada

Phase 4

Completed

Conditions: HIV-1

Interventions: Drug: Zidovudine/lamivudine
Drug: Truvada

First Posted Date: 2006-05-11

Last Posted Date: 2015-08-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 80

Registration Number: NCT00324649

Locations: 🇪🇸
Gilead Sciences, S.L., Madrid, Spain

Safety Study of Once a Day ART and Opiate Substitute.

Phase 4

Completed

Conditions: HIV Infections

First Posted Date: 2006-05-11

Last Posted Date: 2014-03-12

Lead Sponsor: Gilead Sciences

Target Recruit Count: 60

Registration Number: NCT00324688

Locations: 🇩🇪
Gilead Sciences, Munich, Germany

TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Truvada
Drug: Current HAART regimen

First Posted Date: 2006-05-09

Last Posted Date: 2010-01-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 92

Registration Number: NCT00323492

Locations: 🇫🇷
Gilead Sciences, Paris, France

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2006-05-09

Last Posted Date: 2008-07-04

Lead Sponsor: Gilead Sciences

Target Recruit Count: 220

Registration Number: NCT00323544

Locations: 🇬🇧
Gilead Sciences, Cambridge, United Kingdom

SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada

Phase 4

Completed

Conditions: HIV-1 Infection

First Posted Date: 2006-05-09

Last Posted Date: 2008-06-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 50

Registration Number: NCT00323687

Locations: 🇩🇪
Gilead Sciences GmbH, Martinsried, Germany

Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: tenofovir DF
Drug: emtricitabine /tenofovir DF

First Posted Date: 2006-03-28

Last Posted Date: 2011-11-01

Lead Sponsor: Gilead Sciences

Target Recruit Count: 106

Registration Number: NCT00307489

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

Phase 2

Completed

Conditions: HIV
HIV-1
Human Immunodeficiency Virus

First Posted Date: 2006-03-02

Last Posted Date: 2008-07-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 278

Registration Number: NCT00298350

Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Entecavir (ETV)
Drug: Tenofovir disoproxil fumarate (tenofovir DF; TDF)
Drug: Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Drug: TDF placebo
Drug: FTC/TDF placebo
Drug: ETV placebo

First Posted Date: 2006-03-02

Last Posted Date: 2013-04-25

Lead Sponsor: Gilead Sciences

Target Recruit Count: 112

Registration Number: NCT00298363

Locations: 🇵🇱
Wojewodzki Szpital Zakazny, Warsaw, Poland
🇪🇸
Hospital Clinic i Provincial de Barcelona (HCPB), Barcelona, Spain
🇪🇸
Hospital General Universitario Gregorio Maranon, Madrid, Spain

and more 35 locations

Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: hA20-humanized anti-CD20 antibody

First Posted Date: 2006-02-02

Last Posted Date: 2021-08-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 82

Registration Number: NCT00285428

Locations: 🇺🇸
New York Presbyterian Hospital/Cornell Medical Center, New York, New York, United States
🇺🇸
University Hospital of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy